Exelixis, Inc. (EXEL)
Data as of Nov 3, 12:52 PM ETPrices may be delayedHow our data works
Res / Sup are automatic swing levels for educational reference only — not signals or advice.
Prices may be delayed. For informational purposes only — not investment advice.
EXEL key stats
EXEL GlowScore: Active
A 0–100 read on today's activity from volume, momentum and intraday range. Not a buy or sell signal.
About Exelixis, Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
What's moving EXEL today
Updated November 3, 2026As of November 3, 2026, Exelixis, Inc. (EXEL) stock climbed to $73.20, up 4.37% (+$3.07) versus the previous close. On the day, shares have traded between $70.11 and $73.30. That puts EXEL near the top of its 52-week range of $37.58 to $73.30. Exelixis, Inc. operates in the biological products, (no diagnostic substances) space and carries a market capitalization of roughly $16.93 billion, with about 1.19 million shares changing hands.
Latest EXEL news
- Exelixis (EXEL) International Revenue in Focus: Trends and ExpectationsYahoo Finance· Nov 2, 8:15 AM ET
- Earnings Beat Could Be A Game Changer For Exelixis Stock (EXEL)Yahoo Finance· Oct 31, 8:08 AM ET
- Exelixis (EXEL) Beats Q3 Estimates, Is The Stock Fully Priced?Yahoo Finance· Oct 31, 12:20 AM ET
- EXEL Q3 Earnings Beat Estimates on Strong Cabometyx SalesYahoo Finance· Oct 30, 11:46 AM ET
- Exelixis (EXEL) Q3 2026 Earnings Call Transcriptfool.com· Oct 30, 11:00 AM ET
- Exelixis, Inc. Q3 2026 Earnings Call Summaryapp.moby.co· Oct 30, 8:30 AM ET
- What Exelixis (EXEL) Said on Its Q3 Earnings Callmarketbeat.com· Oct 29, 8:14 PM ET
- Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesYahoo Finance· Oct 29, 5:00 PM ET
Source: Yahoo Finance RSS · Updated November 3, 2026
Want EXEL headlines, alerts and AI research in one place? Create a free account →
EXEL buzz on Stocktwits
12,226 watchers$EXEL monster breakout
@cfromhertz· Nov 3, 12:15 PM ET
$EXEL $MRK we’ll take $125 BO offer 😉
@DefenseMania· Nov 3, 10:01 AM ET· Bullish
@ValuJack yeah that 117 vs 69 gap is the part that sticks with me imo on $EXEL. a 1B buyback plus generics blocked to 2030 gives it runway, and that March decision is the next gate. is March the real mover here, or does the buyback keep doing the work til then. the money on th…
@BiotechSwings· Nov 3, 12:41 AM ET
$EXEL Exelixis came up in our momentum screen today. Up almost 80% in a year, but our fair value estimate is still about $117 vs a price around $69. What stands out: sales up 10% last quarter, earnings beat, and they've bought back $1B of their own shares this year. A cour…
@ValuJack· Nov 2, 3:26 PM ET
Looks like industry is pivtoing to basic neccessities and health $EXEL $PG $REPL $CL $KMB Better sense may prevaill
@victorgn· Nov 2, 11:02 AM ET· Bullish
Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →
EXEL Congress & insider trades
Congress amounts are the disclosed ranges; filings can lag the trade date by up to 45 days.
AI research on EXEL
Get an instant AI breakdown of the bull & bear case, key risks, and what analysts are watching.
Not financial advice. This page is for educational purposes only. Data comes from third-party sources, may be delayed or incomplete, and should not be the basis of any investment decision.